KALA BIO, Inc.
KALA · XNASCIK 1479419fmd_06MFA5D2SXXN26D611Z6AHV52DManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Jun 30, 2026, 43 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | – | 6 | 6 | 11 | 4 | 0 | 0 | 0 |
| Research and development | 25 | 29 | 29 | 27 | 18 | 12 | 18 | 19 | 22 | 19 |
| Selling, general and administrative | – | 11 | 35 | 65 | 81 | 105 | 65 | 21 | – | – |
| Total operating expenses | 33 | 40 | 65 | 94 | 103 | 141 | 86 | 40 | 41 | 39 |
| Operating income | (33) | (40) | (65) | (88) | (96) | (130) | (82) | (40) | (41) | (39) |
| Interest expense | 1 | 1 | 3 | 8 | 9 | 8 | 7 | 6 | 6 | 3 |
| Interest and investment income | 0 | 1 | 2 | 2 | 0 | 0 | 1 | 3 | 2 | 1 |
| Other non-operating income (expense) | – | – | – | – | – | (12) | 37 | (3) | 2 | 12 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (33) | (42) | (67) | (94) | (104) | (143) | (45) | (42) | (39) | (27) |
| Net income to common shareholders | (33) | (42) | (67) | (94) | (104) | (143) | (45) | (42) | (39) | (27) |